Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||ADC ST8176AA1|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|ADC ST8176AA1||Trastuzumab-HDACi ST8176AA1|ST8176AA1 ADC|ST8176AA1-ADC||HER2 (ERBB2) Antibody 37||ADC ST8176AA1 is an antibody-drug conjugate comprising Herceptin (trastuzumab), an ERBB2 (HER2) antibody, linked to ST7464AA1, which delivers the HDAC inhibitor to tumor cells expressing ERBB2 (HER2), potentially inhibiting Erbb2 signaling, and resulting in increased DNA damage and apoptosis, and reduced cell proliferation and tumor growth (PMID: 32039017).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|ERBB2 over exp||pancreatic carcinoma||sensitive||ADC ST8176AA1||Preclinical - Pdx||Actionable||In a preclinical study, ADC ST8176AA1 treatment inhibited tumor growth in patient-derived xenograft (PDX) models of pancreatic carcinoma overexpressing ERBB2 (HER2) (PMID: 32039017).||32039017|
|ERBB2 positive||colon carcinoma||sensitive||ADC ST8176AA1||Preclinical - Cell line xenograft||Actionable||In a preclinical study, ADC ST8176AA1 treatment reversed epithelial to mesenchymal (EMT) transition, induced DNA damage, increased apoptosis, and inhibited Erbb2 (Her2) signaling and proliferation of ERBB2 (HER2) expressing colon carcinoma cells in culture, and increased median survival in a cell line xenograft model (PMID: 32039017).||32039017|
|ERBB2 positive||ovarian carcinoma||sensitive||ADC ST8176AA1||Preclinical - Cell line xenograft||Actionable||In a preclinical study, ADC ST8176AA1 treatment induced apoptosis and inhibited proliferation of ERBB2 (HER2) expressing ovary carcinoma cells in culture, and inhibited tumor growth, and increased median survival in cell line xenograft models (PMID: 32039017).||32039017|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|